Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology
Abstract
Poly-(ADP-ribose) polymerase (PARP) inhibitors act in cells with defects in homologous recombination DNA repair (HRR) caused by genomic aberrations such as BRCA mutations. This phenomenon called synthetic lethality is known now to be more common in prostate cancer than previously thought. Olaparib and rucaparib, two PARP inhibitors, were successfully tested in clinical trials for HRR-deficient metastatic castration-resistant prostate cancer. They received a breakthrough US FDA approval in HRR altered metastatic castration-resistant prostate cancer in May 2020. Consequently, the combination of PARP inhibitors with other agents such as androgen receptor pathway inhibitors, immune checkpoint inhibitors or DNA damage inducing chemotherapy are being currently largely studied. In our review, we aim to summarize the key PARP inhibitors published and ongoing trials in prostate cancer.
References
- 1. . Clinical practice. Screening for prostate cancer. N. Engl. J. Med. 365(21), 2013–2019 (2011).
- 2. . Epidemiology of prostate cancer. World J Oncol. 10(2), 63–89 (2019).
- 3. Prostate Cancer Treatment (PDQ®)–Patient Version - National Cancer Institute [Internet] (2020). https://www.cancer.gov/types/prostate/patient/prostate-treatment-pdq
- 4. Prostate cancer - types of treatment [Internet] (2012). https://www.cancer.net/cancer-types/prostate-cancer/types-treatment
- 5. Common treatments for advanced prostate cancer [Internet]. https://www.webmd.com/prostate-cancer/prostate-cancer-advanced-treatments
- 6. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011).
- 7. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138–148 (2013).
- 8. Enzalutamide in metastatic prostate cancer before chemotherapy. N. Engl. J. Med. 371(5), 424–433 (2014).
- 9. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012).
- 10. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 379(26), 2495–2505 (2018).
- 11. Integrative clinical genomics of advanced prostate cancer. Cell 161(5), 1215–1228 (2015).
- 12. . Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst.) 71, 172–176 (2018).
- 13. . Biomarkers for homologous recombination deficiency in cancer. J. Natl Cancer Inst. 110(7), 704–713 (2018).
- 14. PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. Prostate Cancer Prostatic Dis. 23(4), 549–560 (2020).
- 15. . PARP inhibitors: a tsunami of indications in different malignancies. Pharmacogenomics 21(3), 221–230 (2020).
- 16. . Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. Curr Opin Urol. 30(4), 519–526 (2020).
- 17. FDA. Research C for DE and FDA approves olaparib for HRR gene-mutated metastatic castration-resistant prostate cancer (2021). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-olaparib-hrr-gene-mutated-metastatic-castration-resistant-prostate-cancer
- 18. FDA. Research C for DE and FDA grants accelerated approval to rucaparib for BRCA-mutated metastatic castration-resistant prostate cancer. 2021). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-rucaparib-brca-mutated-metastatic-castration-resistant-prostate
- 19. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373(18), 1697–1708 (2015).
- 20. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, Phase 2 trial. Lancet Oncol. 21(1), 162–174 (2020).
- 21. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020).
- 22. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann. Oncol. 30, v327–v328 (2019).
- 23. Pre-specified interim analysis of GALAHAD: a Phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD). Ann. Oncol. 30, v884–v885 (2019).
- 24. . Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int. J. Womens Health 11, 431–437 (2019).
- 25. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, Phase 2 trial. Lancet Oncol. S1470-2045(21)0037 6–4 (2021).
- 26. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, Phase 2 trial. Lancet Oncol. 19(7), 975–986 (2018).
- 27. TALAPRO-2: a two-part, placebo-controlled Phase III study of talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. [Internet]. https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.7_suppl.TPS337
- 28. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results From NCI 9012 - PubMed [Internet]. https://pubmed.ncbi.nlm.nih.gov/29261439/
- 29. . Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction? Ann. Transl. Med. 7(Suppl. 1), S7 (2019).
- 30. 621P Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Ann. Oncol. 31, S513–S514 (2020).
- 31. Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer. Invest. New Drugs 32(5), 904–912 (2014).
- 32. . Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3(1), 81–85 (1997).
- 33. Targeted treatment of prostate cancer. J. Cell. Biochem. 102(3), 571–579 (2007).
- 34. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises. J. Biol. Regul. Homeost. Agents 28(4), 555–563 (2014).
- 35. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 38(32), 3763–3772 (2020).
- 36. . Understanding resistance mechanisms and expanding the therapeutic utility of PARP inhibitors. Cancers (Basel) 9(8), 109 (2017).
- 37. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111–1115 (2008).
- 38. PARP Inhibitors as P-glyoprotein substrates. J. Pharm. Sci. 103(6), 1913–1920 (2014).
- 39. Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov. 3(1), 68–81 (2013).
- 40. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol. Cell. 35(4), 534–541 (2009).
- 41. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell. 46(2), 125–135 (2012).